The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib
Open accessAbstract
Purpose A preliminary analysis demonstrated that local ablative therapy (LAT) can provide short-term control of extra-CNS (eCNS) lesion progression in tyrosine-kinase addicted non-small cell lung cancer (NSCLC) patients. However, little is known about the long-term efficacy and safety of single and multiple courses of radiotherapy when used to treat these sites of progressive disease. This study analyzes the durability and toxicity of radiotherapeutic LAT applied to eCNS disease progression in ALK+ NSCLC patients. Materials and Methods ALK+ NSCLC patients receiving crizotinib manifesting ≤4 discrete sites of eCNS progression were classified as having oligoprogressive disease (OPD). If subsequent progression met OPD criteria, additional courses of LAT were considered. Crizotinib was continued until eCNS progression was beyond OPD criteria or otherwise not suitable for further LAT. Results 33 of 38 patients progressed on crizotinib. Of these, 14 had eCNS progression meeting OPD criteria suitable for radiotherapeutic LAT. Patients with eCNS OPD received 1–3 courses of LAT with radiotherapy. The 6 and 12 month actuarial local lesion control rates (LC) with radiotherapy was 100 and 86%, respectively. The 12 month LC with single-fraction equivalent dose >25 Gy versus ≤25 Gy was 100% vs. 60% (p = 0.01). No acute or late grade >2 radiotherapy-related toxicities were observed. Median overall time on crizotinib among those treated with LAT versus those who progressed but were not suitable for LAT was 28 and 10.1 months, respectively. Patients remaining on crizotinib for >12 months vs ≤12 months had a 2 year OS of 72% vs 12%, respectively (p < 0.0001). Conclusions LAT safely and durably eradicated sites of individual lesion progression in ALK+ NSCLC patients receiving crizotinib. A dose-response relationship for LC was observed. The suppression of OPD on crizotinib by LAT allowed an extended duration of exposure to crizotinib, which was associated with longer OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684
Self-citationLee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., Le, Q.-T., Wakelee, H. A., Graves, E. E., & Loo, B. W. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.05.001 · Cited by 92
Cited by
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A., Lovly, C. M., Goldberg, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0138 · Cited by 328
Self-citationIyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7412 · Cited by 286
Self-citation
Metadata
- Authors
- Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., & Camidge, D. R.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 88
- Issue
- 4
- Pages
- 892-898
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2139483106
- Cited by
- 221
- References
- 4
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. https://app.cochat.ai/papers/10.1016/j.ijrobp.2013.11.010
- The paper
- Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., & Camidge, D. R. (2014). Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2013.11.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.